This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
ErbB mutations in patients with squamous NSCLC: a subanalysis of LUX-Lung 8
In a genetic analysis of 245 patients with squamous cell carcinoma (SqCC)of the lung from the LUX-Lung 8 study, 53 (21.6%) had tumours with at least one ErbB Family mutation.1 Progression-free survival (PFS) and overall survival (OS) were longer with afatinib* versus erlotinib in patients with ErbB wild-type tumours (median PFS: 3.5 vs 2.5 months; hazard ratio[HR]=0.69; 95% confidence interval [CI]: 0.51–0.92; p=0.012; median OS: 8.4 vs 6.6 months; HR=0.81; 95% CI: 0.62–1.05; p=0.115). These effects were more pronounced in afatinib-treated patients with ErbB mutation-positive tumours versus afatinib-treated patients without ErbB mutations (median PFS: 4.9 vs 3.0 months; HR=0.62; 95% CI: 0.37–1.02; p=0.062; median OS: 10.6 vs 8.1 months; HR=0.75; 95% CI: 0.47–1.17; p=0.206). The most marked effect was seen in 12 patients with HER2 mutations.1 The presence of HER2 mutations predicted favourable PFS (interaction p value = 0.006) and OS (interaction p value = 0.003) with afatinib versus erlotinib.1
Goss GD, et al. JAMA Oncol 2018 Jun 14. doi: 10.1001/jamaoncol.2018.0775. [Epub ahead of print].
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue